Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer
posted on
Sep 24, 2020 11:03AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials